Real-world clinical insights and aqueous humor biomarker analysis of diabetic macular edema subtypes classified by OCT following intravitreal injections.

Purpose: This study aimed to observe the morphological changes and visual outcomes in diabetic macular edema (DME) subtypes based on optical coherence tomography classification following intravitreal injection.

Methods: Ninety-four eyes from seventy-eight patients were enrolled between July 1, 2018, and June 30, 2023. Best-corrected visual acuity (BCVA), central subfield thickness, and morphological changes were examined at each follow-up visit.

Topical application of Cap-loaded hydrogels inhibits corneal neovascularization.

Corneal neovascularization (CNV) is a significant risk factor for visual impairment. The efficiency and side effects of current CNV treatments, such as steroids and antivascular endothelial growth factor agents, are still debated. In addition, the bioavailability of topical drugs is usually hindered by tears, blinking, and the corneal anatomy.

DEVELOPMENT AND PSYCHOMETRIC PROPERTIES OF A QUALITY OF LIFE ASSESSMENT TOOL FOR CHINESE PATIENTS UNDERGOING INTRAVITREAL INJECTION (IVI-QOL-23).

Purpose: To develop and assess the psychometric properties of a quality-of-life (QoL) assessment tool for Chinese patients treated with intravitreal injection (IVI) of anti-vascular endothelial growth factor.

Methods: We developed a 31-item IVI-QoL questionnaire using semistructured patient interviews and expert panel consultation, drawing on a study of the literature. After pretesting on a subset of patients undergoing IVI, the questionnaire was pared down to 23 items.

Knowledge, attitudes, and practices of patients with age-related macular degeneration (AMD) towards Anti-VEGF treatment under one-stop intravitreal injection model.

To evaluate the knowledge, attitudes, and practices (KAP) of patients with age-related macular degeneration (AMD) regarding anti-VEGF treatment within a one-stop intravitreal injection service model. A cross-sectional study was conducted from July 1, 2023, to January 31, 2024, at the One-stop Intravitreal Injection Center at Tianjin Medical University Eye Hospital. Data were collected using a specially designed KAP questionnaire.